Increased prevalence of primary drug-resistant pulmonary tuberculosis in immunocompromised patients

Respirology

Volumn 16, Issue 2, 2011, Pages 308-313

  Jiang, Jung Rern ^a   Yen, Shiao Yu ^a   Wang, Jann Yuan ^b  

^a St Joseph's Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

drug resistance; immunodeficiency; infection control; tuberculosis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; COMORBIDITY; FEMALE; HEALTH SURVEYS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 79551511149     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01902.x     Document Type: Article

References (17)

1. Shi WY, Lin T, Chou JH, et al. Country profiles. In:, Kuo HS, (ed.) Taiwan Tuberculosis Control Report 2009. Centers for Disease Control, Department of Health, Taiwan, 2009; 157.
2. Chiang CY, Centis R, Migliori GB,. Drug-resistant tuberculosis: past, present, future. Respirology 2010; 15: 413-32.
3. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am. J. Respir. Crit. Care Med. 1996; 153: 317-24.
4. Bashar M, Alcabes P, Rom WN, et al. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001; 120: 1514-19.
5. Surucuoglu S, Ozkutuk N, Celik P, et al. Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome. Ann. Saudi Med. 2005; 25: 313-18.
6. Suchindran S, Brouwer ES, Van Rie A,. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 2009; 4: e5561.
7. Dewan P, Sosnovskaja A, Thomsen V, et al. High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002. Int. J. Tuberc. Lung Dis. 2005; 9: 170-4.
8. Moniruzzaman A, Elwood RK, Schulzer M, et al. A population-based study of risk factors for drug-resistant TB in British Columbia. Int. J. Tuberc. Lung Dis. 2006; 10: 631-8.
9. Ormerod LP,. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br. Med. Bull. 2005; 73-74: 17-24.
10. Tanrikulu AC, Hosoglu S, Ozekinci T, et al. Risk factors for drug resistant tuberculosis in southeast Turkey. Trop. Doct. 2008; 38: 91-3.
11. Peter CR, Schultz E, Moser K, et al. Drug-resistant pulmonary tuberculosis in the Baja California-San Diego county border population. West. J. Med. 1998; 169: 208-13.
12. Frieden T, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 1993; 328: 521-6.
13. Schwoebel V, Decludt B, de Benoist AC, et al. Multidrug resistant tuberculosis in France 1992-4: two case-control studies. BMJ 1998; 317: 630-1.
14. Fisher-Hoch SP, Whitney E, McCormick JB, et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand. J. Infect. Dis. 2008; 40: 888-93.
15. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am. J. Respir. Crit. Care Med. 1996; 153: 837-40.
16. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 1998; 157: 1881-4.
17. Pablos-Mendez A, Blustein J, Knirsch CA, et al. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am. J. Public Health 1997; 87: 574-9.